Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20625241 | 0.94 | AKR1C3 (0.46) | HTTPOLBNPC1CYP3A4PKM | |
| SCHEMBL13785253 | 0.93 | HTT (0.53) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL2618863 | 0.93 | HTT (0.53) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL2150376 | 0.92 | HTT (0.53) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL16067368 | 0.91 | HTT (0.51) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL20631194 | 0.91 | HTT (0.51) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL2468068 | 0.90 | HTT (0.52) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL29620246 | 0.90 | HTT (0.52) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL875229 | 0.89 | POLB (0.54) | HTTPOLBNPC1CYP3A4LMNA | |
| SCHEMBL29546147 | 0.89 | HTT (0.56) | HTTPOLBNPC1CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110256469-B | Pyrrolobenzodiazepines and conjugates thereof | 麦迪穆有限责任公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-108463253-B | Pyrrolobenzodiazepine conjugates | 麦迪穆有限责任公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-109069663-B | Pyrrolobenzodiazepine conjugates | 麦迪穆有限责任公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-109843335-B | Pyrrolobenzodiazepine conjugates | 麦迪穆有限责任公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20200181101-A1 | BENZAMIDE INHIBITORS OF BACTERIAL LIPOPROTEIN SIGNAL PEPTIDASE | SCRIPPS RESEARCH INST (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200181101-A1 | BENZAMIDE INHIBITORS OF BACTERIAL LIPOPROTEIN SIGNAL PEPTIDASE | SCRIPPS RESEARCH INST (US) | 2020-06-11 | — | — | US | disclosed |
| WO-2019010165-A1 | BENZAMIDE INHIBITORS OF BACTERICAL LIPOPROTEIN SIGNAL PEPTIDASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-01-10 | — | — | WO | disclosed |
| WO-2019010165-A1 | BENZAMIDE INHIBITORS OF BACTERICAL LIPOPROTEIN SIGNAL PEPTIDASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-01-10 | — | — | WO | disclosed |
| US-20030195196-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| EP-1193270-B1 | Pyrrolobenzodiazepines | SPIROGEN LTD (GB) | 2003-05-14 | — | — | EP | disclosed |
| EP-1109811-A2 | PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2001-06-27 | — | — | EP | disclosed |
| EP-1109812-A2 | PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012508-A2 | PYRROLBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012507-A2 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181101-A1 | BENZAMIDE INHIBITORS OF BACTERIAL LIPOPROTEIN SIGNAL PEPTIDASE | LPL, LIPE, LYPLA2 | HTT 3406/4885POLB 3107/4885NPC1 239/4885 |
| US-20030195196-A1 | Pyrrolobenzodiazepines | CNR2, CNR1, HRH3 | HTT 2392/4885POLB 3794/4885NPC1 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.